m_and_a
confidence high
sentiment positive
materiality 0.80
Entero Therapeutics acquires GridAI in share exchange; former GridAI holders to own 82.5% of diluted ENTO
GridAI Technologies Corp.
- Acquired 100% of GridAI for 424,348 common shares (19.99% of outstanding) and 38,801,546 Series H convertible shares.
- Upon conversion (subject to shareholder approval), former GridAI stockholders will own 82.5% of ENTO on a fully diluted basis.
- GridAI is a grid-edge AI platform managing behind-the-meter assets; over $50M invested since 2019.
- ENTO must raise at least $3M in gross proceeds within 30 days post-closing and maintain $2M cash minimum.
- Former GridAI shareholders get right to designate 2 directors initially, eventually 5 of 7 board seats.